European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

Evolution: LUTS-BPH registry from the EAU-RF

Wed, 23 May 2012
LUTSEAU Foundation For Urological Research

In 2009 the European Association of Urology Research Foundation (EAU-RF) started a European registry project to evaluate the impact and management of Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) in five Western European countries.From February 2010 until April 2011 exactly 2072 eligible patients were registered in 5 European countries (the United Kingdom, France, Germany, Italy and Spain) across 86 urological and general practitioner’s centres. So far, the drop-out rate is low, with 91 patients discontinuing participation for several reasons. The aim of the registry is to identify potentially unmet medical needs in a contemporary real-life setting by describing the extent of symptom persistence, worsening and improvement in patients with LUTS/BPH under pharmacological treatment.

The registry will also provide an understanding as to how much current management practices respond to patient needs both in terms of satisfaction with treatment, and improvement in the different domains of quality of life. Satisfaction with treatment as assessed by patients and physicians will be correlated and clinical progression events will be collected as well. The PI of this registry is Prof. Andrea Tubaro (IT).

Two patient populations were studied in the registry:1) patients with LUTS-BPH who presently/recently are untreated with pharmacological agents for LUTS-BPH and start BPH pharmacological treatment at or directly after the baseline visit, and 2) patients with LUTS-BPH presently/recently treated with BPH pharmacological treatment who will continue their BPH pharmacological treatment.

After baseline, the presently/recently untreated patients come for three follow-up visits at 6-, 12 and 24-months. Presently/recently treated patients come for two follow-up visits, at 12 and 24-months. During the visits, patient data (including clinical progression events) and outcomes of the questionnaires are collected in a web-based data management system. The registry also collects data on how physicians follow existing guideline recommendations.

Currently, the patients which started with the registry in the beginning of 2010 are coming for their last, 24-month visit. In April 2013 we expect that the last registered patients will come for the last visit.

After statistical analysis, final publication will follow in December 2013.

Contact details EAU Research Foundation:

• Wanda De Raadt, MSc,Clinical Project ManagerEAU CRO, Arnhem, The Netherlands,Tel: +31 263 890 677w.deraadt@uroweb.org

• Wim Witjes, MD, PhD,Scientific and Clinical Research DirectorEAU CRO, Arnhem, The Netherlands,Tel: +31 263 890 677

This article, including all relevant illustrations, is featured in the March/May issue of European Urology Today.

Share this article

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer